㽶Ƶ

News

The Neuro enrolls Canada’s first patient in a new clinical trial for the treatment of brain tumours

Published: 10 March 2016

Dr. Kevin Petrecca, William Feindel Chair in NeuroOncology at the Montreal Neurological Institute and Hospital of 㽶Ƶ and the MUHC, enrolled and treated Canada’s first patient in a new clinical trial for patients with first or second recurrence of glioblastoma or anaplastic astrocytoma who are undergoing resection. “Brain tumors are extremely challenging to treat, and with 27 Canadians diagnosed each day there is an urgent need for new therapies,” said Dr. Petrecca. “This trial using cancer-selective gene therapy is the kind of cutting-edge investigational treatment that we want to offer patients at our site – the largest specialized neuroscience research and clinical center in Canada. Our team is thrilled to be the first site to open the Toca 5 study in Canada.”

Dr. , Wilkins Family Chair in Brain Tumor Research at the , is the principal investigator for the Toca 5 clinical trial in Canada. Dr. Zadeh and her team are working to open additional clinical trial sites across Canada as soon as we can to enable access to this trial for as many Canadians as possible. For more information on trial sites, please contact Dr. Zadeh at gelareh.zadeh [at] uhn.on.ca.

Learn more about Toca 5 Clinical Trial ()

The Neuro logoMcGill logo

The Neuro (Montreal Neurological Institute-Hospital)is a bilingual academic healthcare institution. We are aMcGill research and teaching institute; delivering high-quality patient care, as part of the Neuroscience Mission of the 㽶Ƶ Health Centre.We areproud to be a Killam Institution, supported by the Killam Trusts.

Back to top